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Background: Polycystic ovarian syndrome is an endocrine disorder with many
complications. This syndrome is a growing concern among adolescents around the
world, with varying reports of its prevalence in different parts of the world.
Objective: This study aimed to determine the prevalence of polycystic ovary syndrome
in adolescents by a systematic review and meta-analysis.
Materials and Methods: In this study, a search for published articles with an English
language limitation and without a time limit was done in different databases (Scopus,
PubMed, and Web of Science, Emabse and Cochrane) in January 2019. The 12 studies
that met the criteria for entering a qualitative assessment scale of 5 and higher were
subjected to systematic review and meta-analysis. Egger and Begg’s tests were used
to check the publication bias. Data were analyzed with STATA software, version 11.1.
Results: Twelve studies were included for meta-analysis. The total number of
participants in the study was 149,477. The average quality score of all studies was 8.67
(range: 5–10). The prevalence of polycystic ovarian syndrome in adolescents based
on the Rotterdam criteria was 11.04% (95% CI: 6.84–16.09%), based on the National
Institute of Health criteria, it was 3.39% (95% CI: 0.28–9.54%), and based on Androgen
Excess and Polycystic Ovary Syndrome Society, it was 8.03% (95% CI: 6.24–10.01%)
Conclusion: The result of this study showed that there is a variation in the prevalence
of PCOS in adolescents based on different criteria; we suggest more community-based
studies among adolescences in different parts of the world.
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1. Introduction
Polycystic ovary syndrome (PCOS) is a common
endocrine disorder in reproductive age women
(1, 2). According to the systematic review and
meta-analysis the prevalence of PCOS in women
of reproductive age estimated from 5% to 18%
(3). PCOS is diagnosed by hyperandrogenism,
ovarian disorder, and polycystic ovaries, although
there are significant variations between individuals
(4). This multi-factorial syndrome initially appears
in puberty (5), and individuals with this disease
may be exposed to the risk of several diseases,
including obesity, metabolic syndrome, insulin
resistance, type-II diabetes, infertility, cancer,
cardiovascular disease, and mental disorders
(6, 7), affecting several dimensions of the quality
of life (8). The evidence suggest that this
syndrome is a disorder presenting in adolescents
due to genetic ovarian malfunction that leads
to the excessive secretion of androgens, and
there is evidence for a genetic basis of PCOS
during the life of the fetus and physiological
hypothalamus-pituitary activation of the ovaries
in the neonatal period and at the beginning
of puberty (9). Congenital venous disorders,
higher-than-average or low birth weight during
pregnancy and childbirth, premature adrenarche,
obesity with acanthosis nigricans, metabolic
syndrome, and pseudo-Cushing’s syndrome or
pseudo acromegaly in early childhood are known
as independent risk factors before menstruation for
developing PCOS (10).
The criteria for the diagnosis of this
syndrome are defined in accordance with
various organizations. The National Institute
of Health (NIH) has designed the NIH criteria, the
American Society of Reproductive Medicine has
designed the Rotterdam criteria, and the Androgen
Excess and Polycystic Ovary Syndrome Society
(AE-PCOS) has designed the AES criteria (11–13).
This heterogeneous disorder leads to the excess
production of androgens especially from the
ovaries, also it is associated with lack of ovulation,
hirsutism, and insulin resistance (14) that is a
relatively common disorder among teenage girls.
The common clinical features such as hirsutism
and menstrual irregularities usually do not appear
until mid- to late adolescence (15). In adolescent
girls, natural characteristics of maturity overlap
with the signs and symptoms of PCOS (16, 17).
Three different sets of diagnostic criteria use to
define the disease in mature women, but there is a
debate on the use of these criteria in adolescents
(18), and it seems the existence of all three groups
of symptoms is essential for the diagnosis of
this syndrome in this younger population. Hence,
etiopathogenic and diagnostic criteria challenges
for PCOS in teens continues (19).
Reports relating to the prevalence of PCOS in
adolescents are rare (20, 21). In a study in India, the
prevalence rate of this syndrome in 15–19-year-old
adolescents based on the Rotterdam criteria was
22.6% and based on the AE-PCOS criteria it was
9.8% (22). In another study on adolescents aged
17–19 in Thailand, the prevalence rate of this
syndrome was 5.29% (23). Studies in Iran have
shown the prevalence rate to be 8.3% to 11.4%
(24, 25).
Despite scattered studies in various parts of
the world, this meta-analysis and systematic review
evaluates the prevalence of PCOS in adolescent
girls worldwide.
2. Materials and Methods
2.1. Search strategy
The search in this meta-analysis and systematic
review was performed by two researchers.
Published articles with an English language
limitation and without a time limit were searched
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in the databases such as Scopus, PubMed, Web of
Science, Emabse, and Cochrane in January 2019.
The search strategy was as follows:
(Prevalence OR Epidemiology OR Cross-
Sectional OR Cross-Sectional Analyses OR
Cross Sectional Analysis AND Adolescence OR
Adolescents OR Female Adolescent OR Teenager
OR Youth OR Teens OR Student AND Polycystic
Ovary Syndrome OR PCOS OR Ovary Syndrome,
Polycystic OR Ovarian Syndrome, Polycystic
OR Stein-Leventhal Syndrome Sclerocystic
Ovary OR Ovary, Sclerocystic OR Sclerocystic
Ovaries).
After searching in the aforementioned
databases, 1,888 articles in the first search
were imported into Endnote and after excluding
duplications (n = 996) and articles with irrelevant
topics (n = 869), finally, 12 articles were included in
the meta-analysis.
2.2. Risk of bias
The quality assessment of the articles was
conducted with a valid tool used for the data related
to prevalence. This quality assessment tool consists
of 10 items and each item has three options "Yes, No,
or Non-transparent." The range of scores is 0–10
and where the option "Yes" is applied, the score is
1 and for other cases, zero is applied. Studies with
a score of 5 and higher were included in the study.
In this scale, sample representative, sample size,
study subjects, data analysis measurement criteria,
and the overall methodological methodological
of the study were examined (26). Table I
shows the results of the quality assessment and
its scores.
2.3. Selection of studies and data
extraction
Next, we reviewed the titles and abstracts of the
articles, and after the removal of irrelevant articles,
the full texts of the relevant articles were extracted
and examined. The diagram of the selected studies
is shown in Figure 1.
After the quality assessment of articles, data
extraction was conducted. The extraction of the
data related to prevalence was conducted by two
researchers on the basis of the standard NIH,
AE-PCOS Society criteria and Rotterdam criteria.
The data extraction form included the author of the
study, year of the study, place of the study, type
of the study, the population of the study and its
features, prevalence of PCOS based on different
criteria, and the prevalence of acne, hirsutism, and
menstrual disorders.
2.4. Eligibility criteria for inclusion of
the study
The observational studies that were included in
the meta-analysis had the following characteristics:
(1) they were conducted on 10-20-year-old females,
(2) PCOS diagnosis was based on one of the
standard criteria (NIH, Rotterdam, and AE-PCOS),
and (3) study samples had no known disorders (such
as Cushing’s, thyroid disorder, and so forth).
2.5. Outcomes
In this study, the primary and main outcome was
the prevalence of PCOS according to the standard
criteria, and the secondary outcome was the
prevalence of hirsutism, acne, and oligomenorrhea.
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Records identified through database
searching: PubMed, Web of Science,
Embase, Scopus, and Cochrane (n = 1888)
Additional records identified through other
sources (n = 0)
Records after duplicates removed (n = 892) 
Records screened (n = 892) 
Records excluded after screening title and
abstract because of none relevance (n = 869)
Full-text articles assessed for
eligibility (n = 23)
Full-text articles excluded, with reasons:
Age range of participants (n = 4)
Inappropriate study design (n = 5)
Estimation prevalence with another criteria (n = 2)
Studies included in qualitative
synthesis (n = 12) 
Studies included in quantitative











Figure 1. Flow diagram of included studies.
2.6. Statistical analysis
The effect size in this study was the prevalence
of PCOS in adolescence, and its variance (with
95% confidence interval) was calculated using the
binomial distribution. The I2 index (I2 statistic) was
calculated for heterogeneity. I2 >50% indicates
significant heterogeneity. In cases where the
studies were heterogeneous, the random effects
model was used to estimate the pooled prevalence.
Egger and Begg’s tests were used to check
publication bias (35). The heterogeneity between
the results of the studies was analyzed using the
Chi squared (χ2) test at a significant level of 5%
(p < 0.05). We used Metaprop command in STATA
for the stability of variance (36). STATA software
(version 11.2) was used to analyze the data.
3. Results
This study aimed to determine the prevalence
of PCOS in adolescent girls. The PRISMA checklist
was used for writing of this study (37). Twelve
studies were included in this meta-analysis study.
The average quality score of all studies was 8.67
(range: 5-10).
The total number of participants in the studies
was 149,477. The mean age of the participants was
16.99 years (95% CI: 16.46-17.52), average body
mass index was 21.09 (95% CI: 20. 3-21.88) kg/m2.
Five studies were related to Iran, four to India, one
to Thailand, one to the United States, and one to
Australia.
3.1. Primary outcomes
The results of this study showed that the
prevalence of PCOS in adolescents was 11.04%
(95% CI: 6.84-16.09%) based on the Rotterdam
criteria and I2 was 96.80%. The NIH criteria was
3.39% (95% CI: 0.28-9.45%) and I2 was 99.32%,
based on AES was 8.03% (95% CI: 6.24-10.01%).
Figures 2 and 3 show overall prevalence.
Additionally in three studies (23, 28, 31),
prevalence based on the Rotterdam criteria
by phenotype clinical hyperandrogenism and
oligomenorhea (OA, HA) was 0.47% (95% CI:
0.1–1.05%), clinical hyperandrogenism phenotype
and Polycystic ovary (HA, PCO) was 1% (95%
CI: 0.38–1.89%), oligomenorhea and Polycystic
ovary (OA, PCO) was 2.6% (95% CI: 0.67–5.68%),
and clinical hyperandrogenism phenotype and
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Polycystic ovary and oligomenorhea (HA, OA, PCO)
was 1.56% (95% CI: 0.44–3.29%).
Table I shows the characteristics of the included
studies. Based on the results of the Begg’s test
(p = 0.244) and Egger’s test (p = 0.155), publication
biases did not exist in the studies (Figure 4).
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Figure 2. The prevalence of polycystic ovary syndrome (NIH criteria) by researcher, year, prevalence and 95% confidence interval
in the world.
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Figure 3. The prevalence of polycystic ovary syndrome (Rotterdam criteria) by researcher, year, prevalence and 95% confidence
interval in the world.
3.2. Secondary outcomes
The prevalence hirsutism in girls with PCOS in
five studies was 18%, the prevalence of acne in
two studies was 35%, and oligomenorrhea in two
studies was 79%.
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Figure 4. Funnel plot for checking publication bias.
4. Discussion
A total of 149,477 girls participated in this
meta-analysis and systematic review. According to
the data, PCOS in adolescents was 11.04% (95% CI:
6.84–16.09%) based on the Rotterdam criteria. The
NIH criteria was 3.39% (95% CI: 0.28–9.45%), and
based on AES was 8.03% (95% CI: 6.24–10.01%).
In a study on 126 Qatari females (age range:
18–30 years), the prevalence of this syndrome
based on the NIH criteria was 33.18% (38). In a study
done on the Iranian population (age range: 17–34
years old), the prevalence based on the NIH criteria
was 7%, based on the Rotterdam criteria it was
15.2%, and based on the AES criteria it was 7.92%
(39). In a study by Ramezani Tehrani and colleagues
on a sample of Iranian women with the average
age of 34.4 +/- 7.6 years, the prevalence rate based
on the NIH criteria was 7.1% (95% CI: 5.4–8.8%)
(40). In a study by Ybarra and colleagues done
on 49 obese Brazilian adolescents, the prevalence
rate of PCOS based on the Rotterdam criteria was
26.4%, based on the AES criteria it was 22.4%,
and based on the NIH criteria it was 20.4% (41).
In a study on 16- to 29-year-old Australian youth,
the prevalence rate based on the NIH criteria was
12% (41). In the meta-analysis study by Ding and
colleagues, the prevalence of PCOS in women of
different races showed that the prevalence rate in
Chinese women was 5.6% (based on the Rotterdam
criteria), which was the lowest prevalence rate,
and in women of Middle Eastern countries it
was 16% based on the Rotterdam criteria (3). A
meta-analytic study in Iran showed the prevalence
of PCOS in Iranian women was 19.5% based on
the Rotterdam criteria (42). In a systematic review
and meta-analysis by Bozdag and colleagues on
women of reproductive age excluding adolescents,
the prevalence rate based on the Rotterdam criteria
was 10% (n = 15 trials) and based on the NIH
criteria the prevalence rate was 6% (n = 18 trials)
(43). It seems the prevalence of this syndrome
in adolescents is almost the same as adults.
Also, as in the study by Bozdag and colleagues,
the prevalence of this syndrome based on the
Rotterdam criteria was double that of the NIH
(43). A study by Rashidi and colleagues reported
that the prevalence of PCOS was 2.9 times more
according to the Rotterdam criteria when compared
with the NIH criteria (44). Although the number of
adolescent studies is few, the evidence shows that
the difference in estimates of prevalence is in part
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due to the diagnostic criteria (45). In adolescents,
the heterogeneity of clinical symptoms of PCOS
and the lack of uniformity in the definition of the
symptoms hinder diagnosis. Moreover, the global
use of PCOS diagnostic criteria is varied (46) and in
general, there is no consensus on how to define
PCOS for teenagers (47). The PCOS signs are
different based on different characteristics such as
the age, race, and weight and add to the challenges
of accurate diagnosis. In adolescents natural
maturity characteristics usually overlap with signs
and symptoms of PCOS, this issue lead to particular
diagnostic problems (16, 48), and based on the
evidence, the debate on the etiopathogenesis,
diagnostic criteria, and suggestions for PCOS in
adolescents continues (19). Moreover, the diet and
lifestyle of individuals in different geographical
regions affect the prevalence rate of this syndrome
in various regions (49). In this study, the prevalence
hirsutism in PCOS girls in five studies was reported
as 18%, the prevalence of acne in two studies
was 35%, and oligomenorrhea in two studies was
reported as 79%. In a study by Ramezani Tehrani and
colleagues, the estimated prevalence of idiopathic
hirsutism and menstrual disorder was 13% and 1.5%,
respectively (50). Nonetheless, in the meta-analytic
study of women in reproductive age (excluding
adolescents), the prevalence of hirsutism was 13%
(8–20%, n = 14 trials), the prevalence of acne was
16% (8–26%, n = 12 trials), and the prevalence of
alopecia was 2% (0–5%, n = 5 trials) (43). In fact,
these results indicate the prevalence of secondary
consequences like acne and hirsutism was more
than that of the adults reported in the study by
Bozdag and colleagues (43).
4.1. Limitation
A limitation of the study was that the number of
studies was based on a small population. In addition,
some diagnostic criteria such as hirsutism fluctuate
among different races. Also, diagnostic challenges
during adolescence, as well as the fact that most
studies were restricted to Iran, were the other
biases of this study. Being limited to the English
language in searching articles caused restrictions
as well.
5. Conclusion
The result of this study showed that there is
a variation in the prevalence of PCOS among
adolescents based on different criteria; we suggest
more community studies among adolescences in
different parts of the world.
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